Compare Stocks: MDWD, SVA, VALN, and SGMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDWD MediWound	$12.66	$14.16	$12.52 ▼ $20.30	$162.68M	0.15	83,063 shs	165,534 shs
SGMT Sagimet Biosciences	$10.55	$8.31	$4.50 ▼ $11.15	$655.79M	3.37	1.43 million shs	573,992 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.67M	0.79	N/A	N/A
VALN Valneva	$6.43	$5.53	$4.75 ▼ $12.23	$610.14M	1.77	186,884 shs	22,287 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDWD MediWound	0.00%	-4.16%	-10.34%	-8.39%	-24.19%
SGMT Sagimet Biosciences	0.00%	+2.93%	+48.38%	+46.73%	+40.48%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
VALN Valneva	0.00%	-7.61%	+29.38%	+8.07%	-27.34%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDWD MediWound	$12.66	$14.16	$12.52 ▼ $20.30	$162.68M	0.15	83,063 shs	165,534 shs
SGMT Sagimet Biosciences	$10.55	$8.31	$4.50 ▼ $11.15	$655.79M	3.37	1.43 million shs	573,992 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.67M	0.79	N/A	N/A
VALN Valneva	$6.43	$5.53	$4.75 ▼ $12.23	$610.14M	1.77	186,884 shs	22,287 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDWD MediWound	0.00%	-4.16%	-10.34%	-8.39%	-24.19%
SGMT Sagimet Biosciences	0.00%	+2.93%	+48.38%	+46.73%	+40.48%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
VALN Valneva	0.00%	-7.61%	+29.38%	+8.07%	-27.34%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MDWD MediWound	2.25	Hold	$33.00	160.66% Upside
SGMT Sagimet Biosciences	2.60	Moderate Buy	$29.17	176.46% Upside
SVA Sinovac Biotech	0.00	N/A	N/A	N/A
VALN Valneva	2.00	Hold	$9.30	44.63% Upside

Current Analyst Ratings Breakdown

Latest MDWD, SVA, VALN, and SGMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$29.00
8/14/2026	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$32.00 ➝ $30.00
8/14/2026	SGMT Sagimet Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/14/2026	SGMT Sagimet Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$12.00 ➝ $29.00
8/12/2026	SGMT Sagimet Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$49.00 ➝ $56.00
8/11/2026	VALN Valneva	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
8/11/2026	VALN Valneva	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/17/2026	MDWD MediWound	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	SGMT Sagimet Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/18/2026	VALN Valneva	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MDWD MediWound	$16.96M	9.59	N/A	N/A	$3.40 per share	3.72
SGMT Sagimet Biosciences	$2M	327.89	N/A	N/A	$3.42 per share	3.08
SVA Sinovac Biotech	$386.01M	1.67	$0.54 per share	11.89	$89.01 per share	0.07
VALN Valneva	$197.56M	3.09	N/A	N/A	$1.39 per share	4.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MDWD MediWound	-$23.88M	-$1.80	N/A	N/A	N/A	-170.10%	-47.24%	-24.27%	11/19/2026 (Estimated)
SGMT Sagimet Biosciences	-$51.04M	-$1.28	N/A	N/A	N/A	N/A	-31.96%	-30.57%	11/12/2026 (Estimated)
SVA Sinovac Biotech	-$59.68M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VALN Valneva	-$130.33M	-$2.11	N/A	14.61	N/A	-110.33%	-153.20%	-39.50%	11/19/2026 (Estimated)

Latest MDWD, SVA, VALN, and SGMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MDWD MediWound	-$0.7617	-$0.77	-$0.0083	-$0.77	$2.59 million	$3.09 million
8/13/2026	Q2 2026	VALN Valneva	-$0.1886	-$0.40	-$0.2114	-$0.38	$44.17 million	$39.37 million
8/11/2026	Q2 2026	SGMT Sagimet Biosciences	-$0.2510	-$0.26	-$0.0090	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MDWD MediWound	N/A	2.32	2.09
SGMT Sagimet Biosciences	N/A	45.03	45.02
SVA Sinovac Biotech	0.04	6.07	5.97
VALN Valneva	2.04	2.16	1.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MDWD MediWound	46.83%
SGMT Sagimet Biosciences	87.86%
SVA Sinovac Biotech	N/A
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
MDWD MediWound	9.20%
SGMT Sagimet Biosciences	11.50%
SVA Sinovac Biotech	12.79%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MDWD MediWound	80	12.85 million	11.67 million	Optionable
SGMT Sagimet Biosciences	8	62.16 million	55.01 million	Optionable
SVA Sinovac Biotech	3,008	99.64 million	86.89 million	Optionable
VALN Valneva	700	94.89 million	80.74 million	Not Optionable

MDWD, SVA, VALN, and SGMT Headlines

Recent News About These Companies

Valneva's Property Sale Buys Breathing Room as Travel-Vaccine Demand Sours

August 30 at 8:16 AM | ad-hoc-news.deA

Valneva SE Sponsored ADR (NASDAQ:VALN) Given Consensus Rating of "Hold" by Analysts

August 30 at 2:28 AM | americanbankingnews.com

Valneva's High-Wire Act: Can Cost Cuts and a Pivotal EMA Review Bridge the Gap to 2026?

August 29 at 12:48 AM | ad-hoc-news.deA

Answers to 3 questions about a potential Lyme vaccine

August 28 at 1:53 PM | msn.com

Valneva SE Sponsored ADR (NASDAQ:VALN) Given Consensus Recommendation of "Hold" by Analysts

August 25, 2026 | marketbeat.com

Valneva's Regulatory Tailwind Collides With a Deepening Loss Profile

August 24, 2026 | ad-hoc-news.deA

Valneva (NASDAQ:VALN) Shares Gap Down - Here's Why

August 24, 2026 | marketbeat.com

Valneva's Analyst Divide Widens as EMA Review Puts Statistical Questions in the Spotlight

August 20, 2026 | ad-hoc-news.deA

Valneva (VALN) Q2 2026 Earnings Call Transcript

August 20, 2026 | finance.yahoo.com

Research Analysts Issue Forecasts for Valneva Q3 Earnings

August 18, 2026 | marketbeat.com

EMA validates marketing authorisation application of Pfizer & Valneva’s PF-07307405, a 6-valent OspA-based Lyme disease vaccine

August 17, 2026 | pharmabiz.comP

EMA validates Pfizer and Valneva’s Lyme disease vaccine

August 17, 2026 | msn.com

Pfizer, Valneva Lyme vaccine starts review in Europe

August 15, 2026 | pharmaphorum.comP

Valneva Shares Climb After Lyme Disease Vaccine Receives EMA Application Acceptance

August 15, 2026 | marketwatch.com

Update: Valneva Shares Gain as Lyme Vaccine Candidate Gets EMA Review

August 15, 2026 | finance.yahoo.com

Valneva (NASDAQ:VALN) Issues Earnings Results, Misses Expectations By $0.17 EPS

August 14, 2026 | marketbeat.com

Valneva (NASDAQ:VALN) Sees Strong Trading Volume - What's Next?

August 14, 2026 | marketbeat.com

A Lyme disease vaccine may finally be on the way. Why did it take so long?

August 14, 2026 | nationalpost.comN

EU to study potential vaccine for Lyme disease: companies

August 14, 2026 | yahoo.com

Valneva SE 2026 Q2 - Results - Earnings Call Presentation

August 14, 2026 | seekingalpha.com

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

August 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD, SVA, VALN, and SGMT Company Descriptions

MediWound NASDAQ:MDWD

$12.66 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Sagimet Biosciences NASDAQ:SGMT

$10.55 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sinovac Biotech NASDAQ:SVA

$6.47 0.00 (0.00%)

As of 08/28/2026

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Valneva NASDAQ:VALN

$6.43 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDWD, SVA, VALN, and SGMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDWD, SVA, VALN, and SGMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDWD, SVA, VALN, and SGMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD, SVA, VALN, and SGMT Company Descriptions

MediWound NASDAQ:MDWD

Sagimet Biosciences NASDAQ:SGMT

Sinovac Biotech NASDAQ:SVA

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDWD, SVA, VALN, and SGMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDWD, SVA, VALN, and SGMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDWD, SVA, VALN, and SGMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD, SVA, VALN, and SGMT Company Descriptions

MediWound NASDAQ:MDWD

Sagimet Biosciences NASDAQ:SGMT

Sinovac Biotech NASDAQ:SVA

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools